A Phase Ib Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast Cancer

Trial Profile

A Phase Ib Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast Cancer

Discontinued
Phase of Trial: Phase I

Latest Information Update: 01 May 2017

At a glance

  • Drugs Doxorubicin liposomal (Primary) ; Lapatinib (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Acronyms CAELYX
  • Most Recent Events

    • 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 01 Feb 2016 Status changed from active, no longer recruiting to discontinued, according to ClinicalTrials.gov record.
    • 31 Dec 2015 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top